WordNet

the 4th letter of the Roman alphabet (同)d

PrepTutorEJDIC

deuteriumの化学記号

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2016/03/26 16:46:23」(JST)

wiki ja

[Wiki ja表示]

DLT、Digital Linear Tape（デジタルリニアテープ）は、磁気テープを使用した大容量補助記憶装置の規格。 1984年にDEC社が同社のMicro VAX II ワークステーション向けに開発したもので、かつてはデータ記憶装置のデファクトスタンダードの一つだった。

DLTテープカートリッジ

当初の型名はTK50と称した。

1994年にクァンタム社 (en:Quantum_Corporation) がDEC社から買い取り、販売および開発を引き継ぎ、記憶容量の向上など改良を加えている。

クァンタムは2001年にSuper DLT (SDLT) 規格の、2006年にはDLT-S4の製品を発売し、DLTtape S4メディアで最大800GB（60MB/秒）までの記録が可能となっている^[1]。このDLT-S4を最後に新規製品は発表されておらず、クァンタムが扱う磁気テープ製品もLTOに移行している。

カートリッジ内部のリールはひとつであり装置側からテープを引き出し、装置側のリールに巻き取りながら読み書きを行う。記録ヘッドは上下に移動しながら複数のトラックに記録する。

脚注

^ “Quantum - DLT-S4”. Quantum Corporation. 2015年11月19日閲覧。

外部リンク

History of DLTtape Technology - Quatum: 1984年から2001年までの歴史
Quantum Corp. DLT drive page

この項目は、コンピュータに関連した書きかけの項目です。この項目を加筆・訂正などしてくださる協力者を求めています（PJ:コンピュータ/P:コンピュータ）。

wiki en

[Wiki en表示]

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 肺分離の手技 lung isolation techniques
2. 大量喀血：初期マネージメント massive hemoptysis initial management
3. 一側肺換気の一般的原則 general principles of one lung ventilation
4. 成人における肺胞蛋白症の診断および治療 diagnosis and treatment of pulmonary alveolar proteinosis in adults
5. 縦隔リンパ節腫脹の外科的マネージメント surgical management of mediastinal lymphadenopathy

English Journal

A phase I/II study of S-1 with sorafenib in patients with advanced hepatocellular carcinoma.

Ooka Y1, Chiba T, Ogasawara S, Arai K, Suzuki E, Tawada A, Yamashita T, Kanai F, Kaneko S, Yokosuka O.Author information 1Department of Gastroenterology and Nephrology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8670, Japan.AbstractBackground Sorafenib is the sole molecular-targeted agent showing a survival benefit in patients with advanced hepatocellular carcinoma (HCC). We evaluated the tolerability and effectiveness of a combination of S-1 with sorafenib in patients with advanced HCC. Methods S-1 was administered during days 1-14 and sorafenib was administered every day. This treatment was repeated every 21 days. In phase I, we determined the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs). The dose of each drug was planned as follows: cohort 1: S-1 48 mg/m2/day and sorafenib 400 mg/day, cohort 2a: S-1 48 mg/m2/day and sorafenib 800 mg/day, cohort 2b: S-1 64 mg/m2/day and sorafenib 400 mg/day, cohort 3: S-1 64 mg/m2/day and sorafenib 800 mg/day, and cohort 4: S-1 80 mg/m2/day and sorafenib 800 mg/day. In phase II, the patients were treated at the MTD to evaluate safety and efficacy. Results Nineteen patients were enrolled in phase I. One of the six patients in cohort 1 and one of the six patients in cohort 3 experienced DLT. None of the three patients in cohort 2a experienced DLT and three of the four patients in cohort 4 experienced DLT. Therefore, cohort 3 was considered the MTD. Subsequently, 26 patients were enrolled in phase II. The most common grade 3/4 toxicities were an increase of aspartate aminotransferase (38.5 %), thrombocytopenia (23.1 %), neutropenia (19.2 %), hyperbilirubinemia (15.4 %), an increase of alanine aminotransferase (15.4 %), hyponatremia (11.5 %), rash (11.5 %), and hypophosphatemia (11.5 %). Sudden death occurred in one patient (3.8 %). A patient (3.8 %) had a partial response, 15 (57.7 %) had stable disease, and 10 (38.5 %) had progressive disease. The median times to progression and overall survival were 2.4 and 10.5 months, respectively. Conclusion The MTD of S-1 and sorafenib in patients with advanced HCC was 64 mg/m2/day and 800 mg/day, respectively. This dose/regimen demonstrated substantial clinical activity among patients with advanced HCC.
Investigational new drugs.Invest New Drugs.2014 Mar 7. [Epub ahead of print]
Background Sorafenib is the sole molecular-targeted agent showing a survival benefit in patients with advanced hepatocellular carcinoma (HCC). We evaluated the tolerability and effectiveness of a combination of S-1 with sorafenib in patients with advanced HCC. Methods S-1 was administered during day
PMID 24599799

Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors.

Bauer S1, Hilger RA2, Mühlenberg T1, Grabellus F3, Nagarajah J4, Hoiczyk M1, Reichardt A5, Ahrens M1, Reichardt P5, Grunewald S1, Scheulen ME2, Pustowka A6, Bock E7, Schuler M1, Pink D5.Author information 11] Sarcoma Center, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Essen, Germany [2] Department of Medical Oncology, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Essen, Germany.2Department of Medical Oncology, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Essen, Germany.31] Sarcoma Center, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Essen, Germany [2] Department of Pathology and Neuropathology, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Essen, Germany.41] Sarcoma Center, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Essen, Germany [2] Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Essen, Germany.5HELIOS Klinikum Berlin-Buch, Sarcoma Center Berlin-Brandenburg, Berlin, Germany.6Novartis Pharma GmbH, Nuremberg, Germany.7Institute for Medical Informatics, Biometry and Epidemiology, Medical Faculty, University Duisburg-Essen, Essen, Germany.AbstractBackground:Panobinostat, a pan-deacetylase inhibitor, overcomes imatinib resistance in preclinical models of gastrointestinal stromal tumours (GIST). Here we determined the maximum tolerated dose (MTD) and dose-limiting toxicities (DLT) of panobinostat in combination with imatinib (IM) for treatment of patients with refractory GIST.Methods:Following a 7-day run-in phase of IM (400 mg per day), escalating doses of panobinostat were added following a '3 plus 3' design. Twelve heavily pretreated GIST patients were enrolled in two dose levels.Results:Most common adverse events were thrombocytopenia, anaemia, fatigue, creatinine elevation, nausea, emesis and diarrhoea. Twenty micrograms of panobinostat and 400 mg IM were declared the MTD. Pharmacologically active concentrations of panobinostat and IM were achieved as evidenced by histone H3 acetylation in blood mononuclear cells in vivo and inhibition of the IM-resistant KIT (D816) mutation in vitro. In FDG-PET-CT scans after IM run-in and following 3 weeks panobinostat treatment, 1 out of 11 evaluable patients showed a metabolic partial response, 7 patients were metabolically stable and 3 patients progressed. Longest treatment duration was 17 weeks (median 6).Conclusion:Panobinostat and IM can be administered at doses achieving target inhibition in vivo. Further clinical exploration of patients with treatment-refractory GIST is warranted. Correlative studies in this trial may help to optimise dosing schedules in GIST.
British journal of cancer.Br J Cancer.2014 Mar 4;110(5):1155-62. doi: 10.1038/bjc.2013.826. Epub 2014 Jan 16.
Background:Panobinostat, a pan-deacetylase inhibitor, overcomes imatinib resistance in preclinical models of gastrointestinal stromal tumours (GIST). Here we determined the maximum tolerated dose (MTD) and dose-limiting toxicities (DLT) of panobinostat in combination with imatinib (IM) for treatment
PMID 24434430

A Bayesian approach to dose-finding studies for cancer therapies: incorporating later cycles of therapy.

Sinclair K1, Whitehead A.Author information 1Medical and Pharmaceutical Statistics Research Unit, Department of Mathematics and Statistics, Lancaster University, U.K.AbstractWe consider phase I dose-finding studies for cytotoxic drugs in cancer, where the objective is identification of a target dose (TD100δ ) associated with the probability δ of a dose-limiting toxicity (DLT). Previous authors have presented a design utilising a Bayesian decision procedure based on a logistic regression model to describe the relationship between dose and the risk of a DLT (LRDP). A cautious prior, chosen to ensure that the first cohort of patients are given the lowest dose, is combined with binary observations of DLTs to update model parameters and choose a safe dose for the next cohort. This process continues with each new cohort of patients. Typically, only DLTs occurring in the first treatment cycle are included. To incorporate data from later cycles, a new Bayesian decision procedure based on an interval-censored survival model (ICSDP) has been developed. This models the probability that the first DLT occurs in each specific cycle via the probability of a DLT during a specific cycle, conditional on having no DLT in any previous cycle. The second cohort of patients start after responses have been obtained from the first cycle of the first cohort, and subsequently, dose selection for each new cohort is based on DLTs observed across all completed cycles for all patients. A simulation study comparing the ICSDP and LRDP showed that the ICSDP induces faster updating of the current estimate of the target dose, leading to shorter trials and fewer patients, whilst keeping the same level of accuracy. Copyright © 2014 John Wiley & Sons, Ltd.
Statistics in medicine.Stat Med.2014 Mar 4. doi: 10.1002/sim.6132. [Epub ahead of print]
We consider phase I dose-finding studies for cytotoxic drugs in cancer, where the objective is identification of a target dose (TD100δ ) associated with the probability δ of a dose-limiting toxicity (DLT). Previous authors have presented a design utilising a Bayesian decision procedure based on a
PMID 24590816

Japanese Journal

動物を用いた外科トレーニングシステム(外科医のトレーニングシステム,会員のための企画)

菱川修司
日本外科学会雑誌 112(3), 193-198, 2011-05-01
NAID 110008661880

バスケットボールゲームにおける高校女子選手の移動行動に関するゲームパフォーマンス分析

大場渉,奥田知靖,菅輝,塩川満久,沖原謙
沖縄大学人文学部紀要 13, 17-27, 2011-03-31
… 分析対象の試合は、第○○回全国高等学校総合体育大会女子準決勝A高校対B高校(74-68でA高校勝利)であり、撮影された画像を基に、DLT法を用いた三次元画像解析法により全選手とボールの移動距離・移動速度を算出した。 …
NAID 110008751922